These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39702250)

  • 1. Comprehensive pan-cancer analysis indicates UCHL5 as a novel cancer biomarker and promotes cervical cancer progression through the Wnt signaling pathway.
    Bao L; Wu Y; Ren Z; Huang Y; Jiang Y; Li K; Xu X; Ye Y; Gui Z
    Biol Direct; 2024 Dec; 19(1):139. PubMed ID: 39702250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer.
    Zhang X; Ren X; Zhang S; Wang Y
    Exp Ther Med; 2024 Dec; 28(6):441. PubMed ID: 39583246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selenoprotein S (SELENOS) is a potential prognostic biomarker for brain lower grade glioma.
    Wang Y; Qu K; Xia Z; Qi M; Du X; Ke Z; Zhang R
    J Trace Elem Med Biol; 2024 Dec; 86():127539. PubMed ID: 39378668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
    Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
    Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Immunological Significance of ANKRD52 in Pan-Cancer.
    Yin HZ; Zhang MC; Wu H
    Biochem Genet; 2024 Dec; 62(6):4335-4358. PubMed ID: 38296907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of
    Shi L; Chen H; Chen J; Palmer JD; Wang L; Sheng L
    Transl Cancer Res; 2024 Nov; 13(11):6298-6314. PubMed ID: 39697738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering potential molecular mechanisms in clear cell renal cell carcinoma based on the ubiquitin-conjugating enzyme E2 related genes: Identifying UBE2C correlates to infiltration of regulatory T cells.
    Feng X; Wang Z; Cen M; Zheng Z; Wang B; Zhao Z; Zhong Z; Zou Y; Lv Q; Li S; Huang L; Huang H; Qiu X
    Biofactors; 2024 Nov; ():. PubMed ID: 39614426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment.
    Chen C; Liu S; Ma Y
    Heliyon; 2024 Nov; 10(22):e40329. PubMed ID: 39624281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CD47 in immune escape of colon cancer and its correlation with heterogeneity of tumor immune microenvironment.
    Tian QS; Zhang C; Bao ZJ; Pei Z
    PeerJ; 2024; 12():e18579. PubMed ID: 39670101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of malic enzyme 1 predicts adverse prognosis in patients with cytogenetically normal acute myeloid leukaemia and promotes leukaemogenesis through the IL-6/JAK2/STAT3 pathways.
    Zhang C; Li W; Wu F; Lu Z; Zeng P; Luo Z; Cao Y; Wen F; Li J; Chen X; Wang F
    Ther Adv Hematol; 2024; 15():20406207241301948. PubMed ID: 39610460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
    Harnan S; Kearns B; Scope A; Schmitt L; Jankovic D; Hamilton J; Srivastava T; Hill H; Ku CC; Ren S; Rothery C; Bojke L; Sculpher M; Woods B
    Health Technol Assess; 2024 Oct; 28(73):1-230. PubMed ID: 39487661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance and immune characteristics of bone morphogenetic proteins (BMPs) family: A pan-cancer multi-omics analysis.
    Chen C; Zhang Y; Lin Y; Shen C; Zhang Z; Wu Z; Qie Y; Zhao G; Hu H
    Technol Health Care; 2024; 32(6):4123-4175. PubMed ID: 39031404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis.
    Shabaninejad H; Kenny RP; Robinson T; Stoniute A; O'Keefe H; Still M; Thornton C; Pearson F; Beyer F; Meader N
    Health Technol Assess; 2024 Oct; 28(75):1-75. PubMed ID: 39487741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex and gender as predictors for allograft and patient-relevant outcomes after kidney transplantation.
    Jayanti S; Beruni NA; Chui JN; Deng D; Liang A; Chong AS; Craig JC; Foster B; Howell M; Kim S; Mannon RB; Sapir-Pichhadze R; Scholes-Robertson NJ; Strauss AT; Jaure A; West L; Cooper TE; Wong G
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD014966. PubMed ID: 39698949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DHX34 as a promising biomarker for prognosis, immunotherapy and chemotherapy in Pan-Cancer: A Comprehensive Analysis and Experimental Validation.
    Liu N; Wang Q; Zhu P; He G; Li Z; Chen T; Yuan J; La T; Tian H; Li Z
    J Cancer; 2024; 15(20):6594-6615. PubMed ID: 39668816
    [No Abstract]   [Full Text] [Related]  

  • 17. Correlation between cervical carcinogenesis and tobacco use by sexual partners.
    Siokos AG; Siokou-Siova O; Tzafetas I
    Hell J Nucl Med; 2019; 22 Suppl 2():184-190. PubMed ID: 31802062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Potential of ESCO2 as a Prognostic and Immunotherapeutic Marker of Pan-Cancer and Its Role in Anti-PD-1 Treatment of Bladder Cancer.
    Guo W; Zhao S; Yan K; Fan Y; Liu J
    Oncology; 2024 Nov; ():1-18. PubMed ID: 39527939
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.